Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bioventus Inc.
Headquarters: Durham, NC, United States of America
Website: http://www.bioventusglobal.com...
Year Founded: 2012
Status: Public
Industry Sector: HealthTechnology
CEO: Robert Claypoole, MBA
Number Of Employees: 970
Enterprise Value: $750,191,610
PE Ratio: -15.57
Exchange/Ticker 1: NASDAQ:BVS
Exchange/Ticker 2: N/A
Latest Market Cap: $635,767,808
BioCentury | Dec 21, 2023
Management Tracks
Larson leaving LianBio as CFO
Plus: Claypoole becomes CEO of Bioventus, and updates from Boston Pharma, Atlas, Quest, Scribe, 858 and more
BioCentury | Mar 1, 2022
Management Tracks
Jones leaving BMS to become CMO of Cullinan
Plus Singleton to join Bioventus as CFO, and updates from Noema, Lycia, Avidity and more
BioCentury | Dec 22, 2021
Management Tracks
BIO’s McMurry-Heath joining Bioventus board
Plus: OSE, Centogene and OncoHealth
BioCentury | Nov 2, 2021
Management Tracks
Zaks, Gujrathi join OrbiMed
Plus: BioTheryX, BioCryst, Redx, Tango, Epizyme and more
BioCentury | Mar 6, 2021
Management Tracks
Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more
BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial for Europe. Winter was previously SVP and head of Europe at Portola Pharmaceuticals Inc. before its acquisition
BioCentury | Feb 12, 2021
Deals
Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta
Shares of Bioventus Inc. (NASDAQ:BVS) rose 48% to $19.21 in its first day of trading after raising $104 million in an IPO through the sale of 8 million shares at $13. $80M series C for Versant-grown
BioCentury | Mar 28, 2020
Management Tracks
Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more
Items per page:
1 - 10 of 15